文献速递垂体与肾上腺疾病

多发性内分泌腺瘤病1型垂体腺瘤的影像学监测:纵向队列研究

Radiological Surveillance for Pituitary Adenomas in Multiple Endocrine Neoplasia Type 1: A Longitudinal Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该回顾性纵向队列研究纳入320例基因确诊的MEN1患者,平均随访14±12年,其中57%存在垂体腺瘤,52%为非功能性腺瘤。非功能性腺瘤的干预率为每100患者年3.1%(CI 2.0-4.7%),且所有需干预者均有症状或垂体功能异常。结论认为影像学监测对非功能性垂体腺瘤的附加获益有限。

要点

  • MEN1患者中57%存在垂体腺瘤,其中非功能性腺瘤占52%。
  • 非功能性腺瘤干预率为每100患者年3.1%(CI 2.0-4.7%)。
  • 所有需干预的非功能性腺瘤患者均有症状或垂体功能异常。

核心结论

  • 在绝大多数MEN1患者中,对非功能性垂体腺瘤的影像学监测除患者报告症状和垂体功能检查外附加获益极小。

研究设计与样本

  • 回顾性纵向队列研究,纳入1977年至2024年9月在NIH临床中心评估的320例基因确诊MEN1患者,平均随访14±12年。

主要发现

  • 320例中182例(57%)有垂体腺瘤,其中95/182(52%)为非功能性腺瘤。
  • 非功能性腺瘤中21/95(22%)在随访期间需要干预,干预率为每100患者年3.1%(CI 2.0-4.7%)。
  • 所有需要干预的非功能性腺瘤患者均有症状或垂体功能检查异常。
  • 38/48(79%)的非功能性腺瘤在平均8.3±6.1年随访中保持稳定。
  • 仅42/518(8.1%)针对非功能性腺瘤的MRI是由临床或生化异常引发的。

关键数值与推荐

  • 非功能性腺瘤干预率:每100患者年3.1%(CI 2.0-4.7%)。
  • 非功能性腺瘤稳定比例:38/48(79%),平均随访8.3±6.1年。
  • 临床或生化异常引发的MRI比例:42/518(8.1%)。

临床怎么用

  • 对于MEN1患者的非功能性垂体腺瘤,可依据患者报告症状和垂体功能检查结果个体化决定影像学监测频率。
  • 个体化影像策略可能避免非功能性微腺瘤患者随访期间约4次MRI检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with multiple endocrine neoplasia type 1 (MEN1) are genetically predisposed to developing tumors of the parathyroid, pancreas, and anterior pituitary. While widespread genetic testing has increased early diagnoses, the value of radiological surveillance for pituitary adenomas in these patients remains unclear. OBJECTIVE: To investigate the impact of pituitary magnetic resonance imaging (MRI) findings on patient management in MEN1. DESIGN: Retrospective longitudinal cohort study. SETTING: NIH Clinical Center. PATIENTS: Genetically confirmed MEN1 evaluated between 1977 and September 2024. MEASURES: Cumulative proportion and rate of intervention for nonfunctional adenomas. RESULTS: Three hundred twenty patients with a mean follow-up duration of 14 ± 12 years were identified. One hundred eighty-two out of 320 patients (57%) had pituitary adenomas, of whom 95/182 (52%) had nonfunctional adenomas. All patients with adenoma had biochemical evaluation at the time of pituitary MRI. There were 21/95 (22%) patients with nonfunctional adenomas that needed an intervention throughout their follow-up. The rate of intervention per 100 patient-years for nonfunctional adenomas was 3.1% (confidence interval 2.0-4.7%). All patients with nonfunctional adenoma who required an intervention reported symptoms or had an abnormal pituitary function test. Tumor volume of 38/48 (79%) nonfunctional adenomas followed over a mean of 8.3 ± 6.1 years remained stable. Only 42/518 (8.1%) MRIs for nonfunctional adenomas were prompted by clinical or biochemical abnormalities. Individualized imaging could have avoided approximately 4 MRIs per patient with nonfunctional microadenoma over their follow-up. CONCLUSION: In an overwhelming majority of patients with MEN1, radiological surveillance for nonfunctional pituitary adenomas offers minimal added benefit beyond patient-reported symptoms and pituitary function testing.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Omotosho YB, Vikram NU, Wright EC, et al. Radiological Surveillance for Pituitary Adenomas in Multiple Endocrine Neoplasia Type 1: A Longitudinal Cohort Study. J Clin Endocrinol Metab. 2026. PMID: 41498210. doi:10.1210/clinem/dgaf704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。